News Releases

September 30, 2019
Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 30, 2019-- Synlogic, Inc. (NASDAQ: SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7 at 4:15...
September 4, 2019
Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the following two new additions to its senior leadership team: This press release...
September 4, 2019
Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)
– Advancing clinical development of SYNB1618 as a novel therapy to potentially serve all patients with phenylketonuria – – Synlogic has initiated a bridging study of a new solid formulation of SYNB1618 to inform dosing in future efficacy study – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep....
August 20, 2019
Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia
– SYNB1020 well tolerated in Phase 1b/2a study, but did not lower blood ammonia in patients with cirrhosis – – Company will focus resources on advancement of SYNB1618, SYNB1891 and new early development programs – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 20, 2019-- Synlogic, Inc....
August 8, 2019
Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- Synlogic, Inc. (NASDAQ: SYBX) announced today that Scott Plevy , M.D., Synlogic’s chief scientific officer, will provide a corporate update at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13 at 9:45 am ET , in New York City ....
August 8, 2019
Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates
– Strong balance sheet supports clinical advancement of lead and emerging Synthetic Biotic ™ programs – –Bridging study to evaluate solid oral formulation of SYNB1618 open and recruiting healthy volunteers – – Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass....
August 1, 2019
Synlogic Announces Second Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its second quarter 2019 financial results after the market...
July 15, 2019
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
– Data demonstrate statistically significant biomarker activity at well-tolerated dose in PKU patients – – Plan to initiate bridging study with new oral solid formulation in Q3 2019 – – Conference call and webcast today, July 15 , at 8:00 a.m. ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....
June 12, 2019
Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines
– Fuels development of Synlogic’s growing pipeline of novel living medicines with technology access and $80.0 million equity investment at a premium – – Applies Ginkgo’s high-throughput synthetic biology platform services to human therapeutics – – Synlogic to host a conference call at 8:00 am ET...
May 22, 2019
Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic...
May 9, 2019
Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update
– Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial...
May 2, 2019
Synlogic Announces First Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market...
Displaying 25 - 36 of 116